Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
24 août 2023 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
19 janv. 2021 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
23 déc. 2020 07h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index
21 déc. 2020 07h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
13 nov. 2020 19h35 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver...
Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares
20 oct. 2020 16h05 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of...
Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
15 oct. 2020 20h35 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of...